Safety and Efficacy of Reduced Dose of Enzalutamide in Patients with Castration-Resistant Prostate Cancer: A Systematic Review.

Pharmaceuticals (Basel) · 2025 · PMC12114795 · PMID 40430550

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Among the studies included in this systematic review, only one study failed to achieve statistical significance in adverse event reduction; however, a favorable trend with dose reduction was reported [ 18 ].

also in 932 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.